Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Clarius Group LLC

Clarius Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 82.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,129 shares of the biopharmaceutical company's stock after buying an additional 509 shares during the quarter. Clarius Group LLC's holdings in Regeneron Pharmaceuticals were worth $716,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in REGN. Rakuten Securities Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC lifted its position in Regeneron Pharmaceuticals by 9.6% during the 4th quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after acquiring an additional 15 shares during the period. Adirondack Trust Co. lifted its position in Regeneron Pharmaceuticals by 4.2% during the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 18 shares during the period. Financial Perspectives Inc lifted its holdings in shares of Regeneron Pharmaceuticals by 10.9% during the fourth quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company's stock worth $137,000 after purchasing an additional 19 shares during the period. Finally, Prestige Wealth Management Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 23.2% during the fourth quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock worth $72,000 after purchasing an additional 19 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN traded down $3.86 during midday trading on Friday, reaching $509.72. 2,259,294 shares of the company's stock were exchanged, compared to its average volume of 889,828. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The stock has a market capitalization of $55.03 billion, a PE ratio of 12.98, a P/E/G ratio of 1.87 and a beta of 0.31. The business's 50-day moving average price is $558.34 and its 200 day moving average price is $640.90.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the firm earned $9.55 earnings per share. The company's revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent research reports. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Bank of America reduced their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, May 30th. Finally, Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research report on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.